|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Alberta Cancer Board |
|---|---|
| Information provided by: | Alberta Cancer Board |
| ClinicalTrials.gov Identifier: | NCT00469196 |
Purpose
Mesothelioma is an incurable cancer involving the lining of the lung. Patients usually suffer progressive symptoms of shortness of breath and chest pain, until they ultimately succumb to the disease. While a very small number of patients qualify for aggressive treatment with surgery, chemotherapy and radiation, and enjoy long-term survival, the vast majority of patients have incurable disease. The treatment options currently available, including chemotherapy and radiation treatment, are only modestly effective at alleviating symptoms and improving life expectancy. This trial explores the use of new radiation technology (tomotherapy), to treat mesothelioma more aggressively than has been possible before. Tomotherapy's ability to treat unusual shaped tumours, particularly when they are wrapped around sensitive normal tissues (the lung), enable higher doses of radiation to be used and this may improve its effectiveness. We will treat 17 patients with tomotherapy and assess the breathing, symptoms, and quality of life of the patients before and after treatment
| Condition | Intervention | Phase |
|---|---|---|
|
Mesothelioma |
Procedure: Tomotherapy |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Tomotherapy Treatment for Mesothelioma |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Rufus Scrimger, MD | 780-432-8517 | rufusscr@cancerboard.ab.ca |
| Canada, Alberta | |
| Cross Cancer Institute | Recruiting |
| Edmonton, Alberta, Canada, T5N 2R8 | |
| Contact: Deanna Gilbert, CCRP 780-432-8352 deannap@cancerboard.ab.ca | |
| Principal Investigator: Rufus Scrimger, MD | |
| Principal Investigator: | Rufus Scrimger, MD | Alberta Cancer Board |
More Information
| Study ID Numbers: | LU-11-0077 |
| Study First Received: | May 2, 2007 |
| Last Updated: | May 2, 2007 |
| ClinicalTrials.gov Identifier: | NCT00469196 History of Changes |
| Health Authority: | Canada: Health Canada |
|
mesothelioma tomotherapy |
|
Neoplasms Neoplasms by Histologic Type Neoplasms, Mesothelial |
Mesothelioma Adenoma Neoplasms, Glandular and Epithelial |